Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 September 2020 | Story Andre Damons | Photo Supplied
Dr Satyajit Tripathy
Dr Satyajit Tripathy, a postdoctoral fellow from the Department of Pharmacology and Physiology, won the medal for the best oral performance at a UNESCO/UNITWIN network web seminar attended by more than 300 people from various institutions around the world.

A postdoctoral fellow in Pharmacology at the University of the Free State (UFS) was awarded a medal for the best oral e-poster presentation (Postdoctoral Fellow category) at a UNESCO/UNITWIN Network web seminar.

The two-day webinar with the theme Current concepts of Environmental Pollution by Electromagnetic field and Coronavirus was held in early August and was attended by more than 300 delegates from approximately 30 institutions from different countries.

Dr Satyajit Tripathy from the Department of Pharmacology won the medal for his outstanding research presentation on Employment of old options to control novel Coronavirus: Pros and Cons (authors: Barsha Dassarma, Satyajit Tripathy, MG Matsabisa). His presentations looked at immunotherapeutic techniques, such as the convalescent plasma (CP) therapy and possible diverse modes of action of the antimalarial drug hydroxychloroquine (HCQ) against COVID-19 infection.

The award will serve as motivation

He was excited to hear that he had won the award, says Dr Tripathy.

“I never thought I would win, but I tried my best. On the topic of possible modes of action of HCQ against the viral infection, we have published in the ‘International Journal of Antimicrobial Agents’ (S Tripathy, B Dassarma, H Chabalala, S Roy, and MG Matsabisa / International Journal of Antimicrobial Agents 56 (2020) 106028). All the authors are grateful to Prof Glen Taylor, Research Director at the UFS, and the UFS Department of Pharmacology, for giving us the opportunity,” says Dr Tripathy. 
According to him, receiving this award is a validation and boost to his confidence. “I am thankful to Prof Motlalepula Matsabisa (supervisor) and Dr Barsha Dassarma (my wife), who are also contributing actively to this project. Moreover, the award is a symbol of respect for my work and the acceptance of a greater responsibility to keep the UFS flag flying high.”
Dr Tripathy goes further to say that it will motivate him to work on HCQ or nano-HCQ delivery research on Coronaviruses. In his doctoral study, it has been found that chitosan-based nanochloroquine delivery increases antimalarial efficacy against rodent parasites. Against the Coronavirus, this type of approach might work to reduce the dose and increase the efficacy of HCQ, explains Dr Tripathy. 

Immediate saviour from the pandemic

In his presentation, Dr Tripathy argues that while the world is finding expedited approvals for the development of vaccines that are time-dependent, preventative, and possibly not a cure, physicians are considering the convalescent plasma (CP) therapy as an immediate saviour, and the antimalarial drug hydroxychloroquine (HCQ) as therapeutic options against COVID-19 infection, after assessing results from larger prospective, randomised, dose-determining controlled clinical trials. 
He concludes that, “Overall, in this situation of unavailability of specific medication, the CP therapy and HCQ treatment might act as an immediate saviour for society from the pandemic.”

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept